BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31779681)

  • 21. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
    Alemayehu A; Sebova K; Fridrichova I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC.
    Morak M; Schackert HK; Rahner N; Betz B; Ebert M; Walldorf C; Royer-Pokora B; Schulmann K; von Knebel-Doeberitz M; Dietmaier W; Keller G; Kerker B; Leitner G; Holinski-Feder E
    Eur J Hum Genet; 2008 Jul; 16(7):804-11. PubMed ID: 18301449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic mosaicism by a de novo MLH1 mutation as a cause of Lynch syndrome.
    Geurts-Giele WR; Rosenberg EH; Rens AV; Leerdam MEV; Dinjens WN; Bleeker FE
    Mol Genet Genomic Med; 2019 Jul; 7(7):e00699. PubMed ID: 31104363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensity-dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles.
    Auclair J; Vaissière T; Desseigne F; Lasset C; Bonadona V; Giraud S; Saurin JC; Joly MO; Leroux D; Faivre L; Audoynaud C; Montmain G; Ruano E; Herceg Z; Puisieux A; Wang Q
    Genes Chromosomes Cancer; 2011 Mar; 50(3):178-85. PubMed ID: 21213371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
    Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
    Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lynch syndrome associated with two MLH1 promoter variants and allelic imbalance of MLH1 expression.
    Hesson LB; Packham D; Kwok CT; Nunez AC; Ng B; Schmidt C; Fields M; Wong JW; Sloane MA; Ward RL
    Hum Mutat; 2015 Jun; 36(6):622-30. PubMed ID: 25762362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MLH1 germline epimutations in selected patients with early-onset non-polyposis colorectal cancer.
    Valle L; Carbonell P; Fernandez V; Dotor AM; Sanz M; Benitez J; Urioste M
    Clin Genet; 2007 Mar; 71(3):232-7. PubMed ID: 17309645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disruption of a -35 kb Enhancer Impairs CTCF Binding and
    Liu Q; Thoms JAI; Nunez AC; Huang Y; Knezevic K; Packham D; Poulos RC; Williams R; Beck D; Hawkins NJ; Ward RL; Wong JWH; Hesson LB; Sloane MA; Pimanda JE
    Clin Cancer Res; 2018 Sep; 24(18):4602-4611. PubMed ID: 29898989
    [No Abstract]   [Full Text] [Related]  

  • 29. Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study.
    Jensen LH; Rasmussen AA; Byriel L; Kuramochi H; Crüger DG; Lindebjerg J; Danenberg PV; Jakobsen A; Danenberg K
    Cell Oncol (Dordr); 2013 Oct; 36(5):411-9. PubMed ID: 24027018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter.
    Yearsley M; Hampel H; Lehman A; Nakagawa H; de la Chapelle A; Frankel WL
    Hum Pathol; 2006 Jul; 37(7):831-8. PubMed ID: 16784982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
    Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
    BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
    Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
    Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome.
    Bouvet D; Bodo S; Munier A; Guillerm E; Bertrand R; Colas C; Duval A; Coulet F; Muleris M
    Gastroenterology; 2019 Aug; 157(2):421-431. PubMed ID: 30998989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inheritance of epigenetic aberrations (constitutional epimutations) in cancer susceptibility.
    Hitchins MP
    Adv Genet; 2010; 70():201-43. PubMed ID: 20920750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome.
    Morak M; Koehler U; Schackert HK; Steinke V; Royer-Pokora B; Schulmann K; Kloor M; Höchter W; Weingart J; Keiling C; Massdorf T; Holinski-Feder E;
    J Med Genet; 2011 Aug; 48(8):513-9. PubMed ID: 21712435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and promoter DNA methylation of MLH1 in colorectal cancer and lung cancer.
    Ma Y; Chen Y; Petersen I
    Pathol Res Pract; 2017 Apr; 213(4):333-338. PubMed ID: 28214209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
    Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
    Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.